ArticleFuture oncology (London, England)2021
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
Shanu ModiPubMed ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papercites it